Graft Versus Host Disease (GVHD)

Carefree: Finding Respite

Thumbnail for video Watch Now

Topic(s)
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Bone Marrow Transplant
COVID-19
Living Well with Bone Marrow Failure
Managing Your Treatment
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pediatric Bone Marrow Failure Diseases
Related Bone Marrow Failure Diseases and Malignancies
In this webinar, Jane Hamilton discusses the benefits of respite care for caregivers. Learn tips and tools to hire a respite worker, how to partner and share the care.

Managing Treatment Symptoms with Diet

Thumbnail for video Watch Now

Topic(s)
Managing Your Treatment
In this webinar, Joanna Myers Casale, RD, CSO, discusses how the foods patients choose can help them cope with side effects, such as loss of appetite, nausea, vomiting, diarrhea, chewing and swallowing difficulties, and taste changes. The recording includes questions from…

Living with Bone Marrow Failure: Stress Management and Survivorship

Thumbnail for video Watch Now

Topic(s)
Living Well with Bone Marrow Failure
Presenter(s)
Areej El-Jawahri, MD
Areej El-Jawahri, MD, and Elyse R. Park, PhD teach patients coping strategies and practical tips for easing the stress of living with a bone marrow failure disease. Patients with aplastic anemia, PNH, or MDS benefit from viewing this recorded program.

Effective treatment of low risk acute GVHD with itacitinib monotherapy

Original Publication Date
Article Source
External Web Content
Key Points Itacitinib monotherapy is as effective as systemic corticosteroids for the treatment of low risk acute GVHD. Itacitinib monotherapy resulted in fewer serious infections compared to systemic corticosteroids. The standard primary treatment for acute graft vs host disease…
Subscribe to Graft Versus Host Disease (GVHD)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.